Latest Tapentadol Stories

BEDMINSTER, N.J. and SYDNEY, July 26 /PRNewswire-FirstCall/ -- QRxPharma (ASX: QRX and Pink Sheets: QRXPY) reported today positive outcomes of its European Scientific Advice meetings on the development and registration of MoxDuo IR, an immediate release Dual-Opioid(TM) pain therapy. The Company is currently completing pivotal Phase 3 trials required for filing a New Drug Application (NDA) for MoxDuo IR with the United States Food and Drug Administration (FDA). QRxPharma intends to submit a...

RARITAN, N.J., July 19 /PRNewswire/ -- A Phase 3 open-label study, recently published online by Pain Practice, has compared tapentadol extended release (ER) tablets, an investigational pain medication, to an existing prescription pain medication, oxycodone controlled release (CR) tablets. The study found tapentadol ER was associated with a lower overall incidence of gastrointestinal adverse events than oxycodone CR (tapentadol ER, 52.0 percent; oxycodone CR, 64.1 percent) in patients with...

STAMFORD, Conn., July 1 /PRNewswire/ -- Purdue Pharma L.P. announced today that the U.S. Food and Drug Administration (FDA) approved Butrans(TM) (buprenorphine) Transdermal System CIII for the management of moderate to severe chronic pain in patients requiring a continuous, around-the-clock opioid analgesic for an extended period of time. Butrans Transdermal System is an analgesic product that delivers continuous release of medication for seven days. "Healthcare professionals now have an...

BLUE BELL, Pa., June 22 /PRNewswire/ -- TheraQuest Biosciences, Inc., a clinical stage pain management company today unveiled its analgesic product pipeline. TheraQuest also announced the launch of its new corporate website at http://www.theraquestinc.com. Najib Babul, PharmD, President and Chief Executive Officer, said, "After a careful strategic review of our pipeline, we have realigned our development efforts to focus on chronic pain products with the largest market potential and...

MELBOURNE, Australia and SAN FRANCISCO, May 28 /PRNewswire/ -- Relevare Pharmaceuticals Ltd. will present its recent Phase IIa proof-of-concept clinical trial data and extension study results for CNSB015 (flupirtine), its lead repositioned compound, at the Third International Congress on Neuropathic Pain on May 27 -30 in Athens, Greece. Dr. Kate Cherry, MD, PhD, Head of the Neuropathy and Drug Toxicity Group at the Burnet Institute in Melbourne, Australia will share the results of the...

WALTHAM, Mass., May 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that 82 percent of surveyed physicians that had prescribed Ortho-McNeil's novel dual-acting opioid Nucynta (tapentadol) indicate that it has comparable efficacy to immediate-release oxycodone, although only 36 percent of surveyed physicians indicate that it was more tolerable with regard to nausea and vomiting, side effects common...

BALTIMORE, May 7 /PRNewswire/ -- A post-hoc analysis of a Phase 3 safety study demonstrated that NUCYNTA® (tapentadol) tablets were associated with a lower incidence of nausea, vomiting and constipation when compared to oxycodone immediate release (IR) tablets in elderly patients with moderate to severe low-back or osteoarthritis pain. These data will be presented during a poster session today at the 29th Annual Scientific Meeting of the American Pain Society (APS), and are supported by...

Data Demonstrate Dual-Opioid(TM) Provides Significantly Better Pain Relief Compared to Component Doses; Study Goals and Secondary Endpoints Met BEDMINSTER, N.J. and SYDNEY, Australia, May 4 /PRNewswire/ -- QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today the release of additional pivotal Phase 3 trial data for MoxDuo IR, an immediate-release Dual-Opioid pain therapy. Required for New Drug Application (NDA) submission with the United States Food and Drug Administration (FDA), this...

RARITAN, N.J., May 3 /PRNewswire/ -- Data on tapentadol for the relief of acute and chronic pain, as well as patient and prescriber perceptions of oxycodone immediate-release treatments, will be presented at the 29th Annual Scientific Meeting of the American Pain Society (APS) May 6-8, 2010. Four of the 12 poster presentations will review analyses of tapentadol data, including a post-hoc analysis of a Phase 3 tolerability study on NUCYNTA® (tapentadol) tablets for acute pain in elderly...

DENVER, April 28 /PRNewswire/ -- Forensic Laboratories, a Denver-based laboratory specializing in toxicology services for drug abuse, has been named one of 50 Colorado Companies to Watch for 2010. Colorado Companies to Watch is hosted by the Colorado Office of Economic Development and International Trade in partnership with the Edward Lowe Foundation. The award recognizes second-stage companies that are developing valuable products and services, creating jobs, enriching communities, and...